Q-omics provides the consensus-scored RPSAP46 profile across patient tissues and cancer cell-line models. RPSAP46 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPSAP46 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPSAP46 RNA expression shows 11,429 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where RPSAP46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP46 survival associations across molecular data types. RPSAP46 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP46 RNA expression–survival associations across cancer types. High RPSAP46 expression shows unfavorable associations in KICH, ACC, SARC, KIRC and STAD, but favorable associations in READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for RPSAP46 RNA expression.
This table summarizes RPSAP46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP46 shows higher tumor expression in COAD, LIHC, LUAD, KIRC, LUSC and BLCA. The COAD box plot shows higher RPSAP46 RNA expression in tumor versus normal tissue (log2 FC = +0.837, t-test p < 0.001).
This table shows molecular features associated with RPSAP46 in patient tissues and cancer cell lines. In patient samples, RPSAP46 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
